HK Stock Market Move | METIS TECHBIO-P(07666) rose more than 8% in early trading, the fifth set of standards for the Sci-Tech Innovation Board has expanded, the AI drug delivery track may usher in a new opportunity.

METIS TECHBIO-P(07666) rose more than 8% in early trading, as of the time of writing, it has risen 6.72%, to HK$14.76, with a turnover of HK$129.89 million. On the news front, the fifth set of listing standards for the Science and Technology Innovation Board has been expanded to the field of artificial intelligence large models. According to Shanghai Securities News, an official from Metis Techbio stated that this means that domestic enterprises with large models and AI deepening capabilities will have a more accessible direct financing channel. The intersection of "AI + biotechnology" represented by AI pharmaceuticals is also expected to receive more institutional support from the capital market. The official believes that the expansion of the fifth set of standards for the Science and Technology Innovation Board to the AI field, as well as the inclusion of future industries such as biomanufacturing in the support range, may lead to clearer institutional expectations for cross-sector races such as AI drug delivery, helping the industry form a more stable innovation ecosystem. It is worth noting that recently, Metis Techbio announced a strategic alliance with the healthcare investment and innovation platform Deerfield. Deerfield manages assets exceeding $16 billion and has been deeply involved in the growth of medical health enterprises such as Sage Therapeutics and Alnylam. This collaboration will integrate Metis Techbio's proprietary technology in AI-driven protein engineering, in vivo immunotherapy, and programmable biopharmaceuticals with Deerfield's deep industry experience in translational medicine, clinical development, and global cooperation.